<button id="eiezk"><video id="eiezk"></video></button>

產(chǎn)品名稱

LY 333531 mesylate - Ruboxistaurin

產(chǎn)品貨號

產(chǎn)品價格

現(xiàn)貨詢價，電話：010-67529703

產(chǎn)品規(guī)格

產(chǎn)品品牌

axonmedchem

產(chǎn)品概述

產(chǎn)品詳情

LY 333531 mesylate - Ruboxistaurin

Based on 377 reference(s) in Google Scholar 10 10 377

Axon 1401

CAS [192050-59-2]

MF C28H28N4O3.CH4O3S
MW 564.65

Purity: 99%
Soluble in DMSO

LY 333531 mesylate

Description

Orally active protein kinase C β (PKC-β) specific inhibitor; a salt form that is five times more?water-soluble than its hydrochloride salt.
The hydrochloride salt of LY 333531 (Axon 2362) is available as well.?

Ruboxistaurin: LY 333531. Drug R. D. 2007, 8(3), 193-199.

LY-333531 mesylate hydrate. Drugs Fut. 2000, 25(10), 1017.

GL Engel et al. Salt form selection and characterization of LY333531 mesylate monohydrate. Int. J. Pharmaceutics 2000, 198(2), 239-247.

MR Jirousek et al. (S)-13-[(dimethylamino)methyl]-10,11,14,15-tetrahydro-4,9:16, 21-dimetheno-1H, 13H-dibenzo[e,k]pyrrolo[3,4-h][1,4,13]oxadiazacy clohexadecene-1,3(2H)-dione (LY333531) and related analogues: (...). J. Med. Chem. 1996, 39, 2664.

Y Wu et al. Protein kinase C beta inhibitor LY333531 attenuates intercellular adhesion molecule-1 and monocyte chemotactic protein-1 expression in the kidney in diabetic rats. J. Pharmacol. Sci. 2006, 101(4), 335-343.

List of publications using LY 333531 mesylate (Axon 1401) purchased from Axon Medchem

Certificate of Analysis
Material Safety Data Sheet

Cell Signaling & Oncology Immunology Pain & Inflammation NF-κB PI3K-Akt-mTOR EC 2.7.11.13 PKC

PKC-β inhibitor

Chemical name

13-((Dimethylamino)methyl)-10,11,14,15-tetrahydro-4,9:16,21 -dimetheno-1H,13H-dibenzo(e,k)pyrrolo(3,4-h)(1,4,13) oxadiazacyclohexadecene-1,3(2H)-dione methanesulfonate

Parent CAS No.

[169939-94-0]

產(chǎn)品資料

<button id="eiezk"><video id="eiezk"></video></button>